文献速递炎症性肠病

慢性肾脏病中炎症性肠病药物的处方:实用指南

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide.
PubMed 文献 · Aliment Pharmacol Ther · 2025-07-02

慢性肾脏病(CKD)在炎症性肠病(IBD)患者中日益常见,但晚期CKD患者的药代动力学资料有限。本文通过叙述性综述截至2025年3月31日的文献,为IBD合并CKD患者的药物治疗提供循证指导,结论为多数IBD疗法尤其生物制剂在CKD(含肾脏替代治疗)中似安全有效,传统疗法与JAK抑制剂需谨慎。

要点

  • 美沙拉秦可致急性间质性肾炎,钙调神经磷酸酶抑制剂与肾毒性相关。
  • 甲氨蝶呤在晚期肾病(含肾脏替代治疗)禁用,因毒性和骨髓抑制风险更高。
  • 晚期肾病应考���硫嘌呤剂量调整;生物制剂在肾功能不全(含血液透析)中似安全。

核心结论

  • 多数IBD疗法尤其生物制剂在CKD患者(含接受肾脏替代治疗者)中似安全有效,使用传统疗法和JAK抑制剂时应谨慎。

研究设计与样本

  • 叙述性综述,检索截至2025年3月31日的文献,聚焦当前IBD治疗在CKD尤其晚期肾病和肾脏替代治疗中的应用。

主要发现

  • 美沙拉秦可导致急性间质性肾炎,钙调神经磷酸酶抑制剂与肾毒性相关。
  • 甲氨蝶呤在晚期肾病(包括肾脏替代治疗期间)禁用,因毒性和骨髓抑制风险更高。
  • 晚期肾病应考虑硫嘌呤剂量调整,因代谢物蓄积。
  • 单克隆抗体包括抗肿瘤坏死因子、抗整合素和抗白介素12/23疗法在肾功能不全(含血液透析)中似安全。
  • 小分子疗法数据有限;药物代谢特征提示其在CKD中安全,但JAK抑制剂(包括托法替布和阿帕替尼)在晚期肾病应考虑减量。

关键数值与推荐

  • 甲氨蝶呤在晚期肾病包括肾脏替代治疗期间禁用。
  • 晚期肾病应考虑硫嘌呤剂量调整。
  • JAK抑制剂包括托法替布和阿帕替尼在晚期肾病应考虑减量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 晚期CKD患者的IBD药物药代动力学特征研究尚不充分。
  • 小分子疗法可用数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of chronic kidney disease (CKD) in patients with inflammatory bowel disease (IBD) is increasing. The pharmacokinetic profiles of IBD medications in patients with advanced-stage CKD are not well studied. AIM: To provide evidence-based guidance on the use of medical therapies in patients with IBD and CKD. METHODS: We conducted a narrative review of literature up to 31 March 2025 on studies of therapies currently used for the treatment of IBD in the setting of CKD, with a focus on advanced kidney disease and use in renal replacement therapy. RESULTS: Mesalazine can cause acute interstitial nephritis. Calcineurin inhibitors have been associated with nephrotoxicity. Methotrexate is contraindicated in advanced renal disease, including while on renal replacement therapy, due to higher risks of toxicity and myelosuppression. Dose adjustment of thiopurines should be considered in advanced renal disease due to metabolite accumulation. Monoclonal antibodies, including anti-tumour necrosis factor therapy, anti-integrin therapy and anti-interleukin 12/23 therapies, appear to be safe in renal insufficiency, including haemodialysis. There is limited data available for small molecule therapies; drug metabolism profiles suggest they are safe in CKD, although, for Janus kinase (JAK) inhibitors, including tofacitinib and upadacitinib, dose reduction should be considered in advanced renal disease. CONCLUSION: Most therapies used in IBD, particularly biologic therapies, appear safe and effective when used in patients with CKD, including those on renal replacement therapy. Caution should be considered when using conventional therapies and JAK inhibitors.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chen L, Srinivasan A, Choy SW, et al. Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide. Aliment Pharmacol Ther. 2025. PMID: 40601470. doi:10.1111/apt.70262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。